ReviewCureus2025
Stigma, Bullying, and Resilience: Psychosocial Outcomes in Marginalized Adolescents With Visible Dermatologic Conditions.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Psychological impact and quality of life in pediatric patients with chronic skin disorders: a systematic review (2010-2025).Frontiers in pediatrics · 2026Pooled it
- Skin Health Literacy in Ontario Secondary Schools: An Overlooked Opportunity for Preventive Health Education.The Journal of school health · 2026Article
- The Psychiatric Comorbidities in Adolescents With Atopic Dermatitis: A Real-World Study of Propensity-Matched Cohorts.International journal of dermatology · 2026Article
- Psychocutaneous Disorders in Pediatric and Adolescent Populations: A Narrative Review.American journal of clinical dermatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visible skin diseases such as acne, eczema, vitiligo, and keloids exert a disproportionate psychosocial burden on marginalized adolescents, particularly among Indigenous, Latinx, and migrant youth. This review illuminates how the cycle of stigma, bullying (both in-person and online), and discrimination is amplified by intersecting cultural, racial, and socioeconomic factors, leading to elevated rates of depression, anxiety, self-harm, and suicide risk. However, despite the gravity of these challenges, psychosocial distress remains routinely underdiagnosed and undertreated in these populations, with significant barriers to mental health care and a lack of culturally competent interventions. Drawing from a broad and interdisciplinary evidence base, we explore not only the epidemiology and risk factors unique to minoritized youth but also the powerful influence of cultural identity, family support, traditional practices, and peer mentorship in shaping resilience. Our review uniquely highlights integrative and creative therapies as promising adjuncts to conventional care. We emphasize the centrality of internalized stigma as a therapeutic target and urge a shift toward trauma-informed care. The findings presented call for coordinated action among dermatologists, pediatricians, psychiatrists, psychologists, educators, and family members as key stakeholders in supporting the psychosocial needs of adolescents with visible skin disease. We recommend systematic psychosocial screening, routine use of validated quality-of-life and stigma measures, family- and community-centered support, and the integration of mental health resources into dermatologic care. Ultimately, by embracing culturally sensitive, multi-level strategies and addressing persistent policy and research gaps, we can not only mitigate the harms of visible skin disease but also transform vulnerability into resilience and agency for the most underserved youth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.